Formoterol fumarate dihydrate (DrugBank: Formoterol)
3 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
85 | Idiopathic interstitial pneumonia | 1 |
228 | Bronchiolitis obliterans | 0 |
299 | Cystic fibrosis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2013-004404-19-GB (EUCTR) | 07/05/2014 | 25/03/2014 | Effect of FostairĀ® on biomarkers of platelet adhesion in Idiopathic pulmonary fibrosis | A Randomized, Double-blind, Placebo-controlled, Crossover Study toAssess the Effect of 28 Day Treatment with FostairĀ® pMDI 200/12 on biomarkers of platelet adhesion in Patients with Idiopathic pulmonary fibrosis. - Effect of FostairĀ® pMDI on biomarkers of platelet adhesion in IPF | Idiopathic pulmonary fibrosis MedDRA version: 16.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Fostair INN or Proposed INN: beclometasone dipropionate INN or Proposed INN: formoterol fumarate dihydrate | Hull and East Yorkshire Hospitals NHS Trust | NULL | Not Recruiting | Female: yes Male: yes | United Kingdom |